Dr. Silk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana-Farber Cancer Institute
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6571
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 2011 - 2014
- UPMC Medical EducationResidency, Internal Medicine, 2008 - 2011
- University of Pittsburgh School of MedicineClass of 2008
- Swarthmore CollegeBA, Biology, 1997 - 2001
- Swarthmore CollegeB.S., Biology (concentration in Environmental Studies), 2001
- University of Pittsburgh School of MedicineM.S., Clinical Research
Certifications & Licensure
- MA State Medical License 2018 - 2025
- NJ State Medical License 2014 - 2019
- MI State Medical License 2011 - 2014
- PA State Medical License 2008 - 2011
Awards, Honors, & Recognition
- Project Member Team Award (PMTA) National Institutes of Health (NIH) Cancer Therapeutics and Evaluation, 2015
- Excellence in Research Award, Hematology/ Oncology Fellowship Program University of Michigan, 2014
- Outstanding Clinical Research Paper Award University of Michigan, 2013
- Join now to see all
Clinical Trials
- A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Start of enrollment: 2014 May 01
- Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) Start of enrollment: 2015 Dec 17
- Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Start of enrollment: 2017 Mar 21
- Join now to see all
Publications & Presentations
PubMed
- 1283 citationsManaging toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Wor...Igor Puzanov, Adi Diab, K. Abdallah, Clifton O. Bingham, C. Brogdon
Journal for Immunotherapy of Cancer. 2017-11-21 - 3 citationsNeoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.Emily Y Kim, Emily S Ruiz, Mia S DeSimone, Sophia Z Shalhout, Glenn J Hanna
JAMA Otolaryngology-- Head & Neck Surgery. 2024-05-01 - 99 citationsOncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.Sachin R. Jhawar, Aditya Thandoni, Praveen K. Bommareddy, Suemair Hassan, Frederick J. Kohlhapp
Frontiers in Oncology. 2017-09-11
Journal Articles
- Phase I Trial of ALT-803, a Novel Recombinant Interleukin-15 Complex, in Patients with Advanced Solid TumorsJeffrey S Miller, Shernan G Holtan, Sylvia M Lee, Chihiro Morishima, Ann W Silk, Clinical Cancer Research
- Clinical characterization of colitis arising from anti-PD-1 based therapyWang DY, Mooradian MJ, Kim DW, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert ..., OncoImmunol, 1/1/2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaWeber J, Mandala M, Del Vecchio M, and the CheckMate 238 Collaborators (Silk AW), N Engl J Med, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.Stein MN, Malhotra J, Malhotra U, Silk AW, Chan N, Rodriguez-Rodriguez L, Aisner J, Aiken R, Newman J, Sadimin E, Saunders T, Frankel M, Kareddula A, El-Deiry WS, Tara..., J Clin Oncol, 1/1/2018
- A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carci...Silk AW, LeBoeuf NR, Rabinowits G, Puzanov I, Burgess MA, Devata S, Moore D, Goydos JS, Chen HX, Kaufman H, Zloza A, Mehnert JM, ASCO-SITC Clinical Immuno-Oncology Symposium; New Jersey Cancer Retreat, San Francisco, CA, 1/1/2018
- A Phase I Study to Evaluate the Safety of Trigriluzole (BHV-4157) in Combination with PD-1 Blocking Antibodies.Silk AW, Berman R, Coric V, Ruggiero L, Reitz AB, Shih W, Kane MP, Mehnert JM, Pelletier JC, Zloza A, Goydos JS, ASCO-SITC Clinical Immuno-Oncology Symposium; New Jersey Cancer Retreat, San Francisco, CA, 1/1/2018
- Join now to see all
Lectures
- Oncolytic Viral Therapy in Melanoma and Merkel Cell Carcinoma: What�s Good for the Goose is Good for the GanderUniversity of Pittsburgh Medical Center, Pittsburgh, PA - 1/1/2018
- Oncolytic Viral TherapyRutgers Robert Wood Johnson Medical School - 1/1/2018
- Practical Radiology for FellowsRutgers Robert Wood Johnson Medical School - 1/1/2018
- Join now to see all
Press Mentions
- What Is Basal Cell Carcinoma, the Skin Cancer Biden Just HadMarch 3rd, 2023
- Society for Immunotherapy of Cancer (SITC) Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Nonmelanoma Skin CancerAugust 3rd, 2022
- New Cancer-Killing Virus Therapy Shows Promise Against Inoperable Skin CancersMay 24th, 2021
- Join now to see all
Grant Support
- Combination oncolytic virus and PD-1 blockade for melanoma treatmentGateway for Cancer Research2016–2018
Professional Memberships
- Member
- Society for the Immunotherapy of Cancer (SITC)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: